<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488706</url>
  </required_header>
  <id_info>
    <org_study_id>CMx-CTC-PC-001</org_study_id>
    <nct_id>NCT03488706</nct_id>
  </id_info>
  <brief_title>Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level</brief_title>
  <official_title>Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellMaxLife</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellMaxLife</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer screening with PSA is plagued by high rate of unnecessary prostate biopsies,
      especially in the &quot;gray zone&quot; (4.00ng/ml e 10.99ng/ml). We introduce a new
      circulating-tumor-cell (CTC) biomarker for detection of prostate cancer in patients in the
      PSA &quot;gray zone&quot; level, with the clinically verified potential to substantially decrease the
      number of unnecessary prostate biopsies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Anticipated">June 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating tumor cells detection</measure>
    <time_frame>Prior to prostate biopsy</time_frame>
    <description>Using a circulating-tumor-cell (CTC) test to detect prostate cancer in patients in the PSA &quot;gray zone&quot; level</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Gray Zone Group</arm_group_label>
    <description>The gray zone group PSA between 4.00 to 10.99 ng/ml.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        PSA 4.00- 10.99 ng/ml patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects are willing to sign the informed consent and agree to comply with the study
             procedures.

          -  Age from 20 to 99 years old

          -  Subjects with a PSA 4.00- 10.99 ng/ml and will receive biopsy within 3 months

        Exclusion Criteria:

          -  Age &lt; 20 years

          -  Refuse to sign the informed consent form

          -  Received regional anesthesia and general anesthesia within one month

          -  Previous cancer history

          -  Autoimmune diseases

          -  Chronic inflammatory diseases

          -  Diagnosed with colorectal polyps or adenomas

          -  Acute inflammatory or infectious diseases in three months

          -  Other diseases decided by PI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ying-Hsu Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joy Chang</last_name>
    <phone>+886-2-26558455</phone>
    <phone_ext>404</phone_ext>
    <email>joy@cellmaxlife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying-Hsu Chang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

